Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Jain

Showing results (381-390 of 420) with videos related to

Pageof 42
Sort By:
Transplantation and Cellular Therapy|April 4, 2022
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell TherapyAasha I Hoogland, Anna Barata, Jennifer Logue, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 9, 2019
Respiratory health status is associated with treatment outcomes in pulmonary tuberculosisA N Gupte, S Selvaraju, M Paradkar, et al.
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Cancer Medicine|February 28, 2021
Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucelAasha I Hoogland, Reena V Jayani, Aaron Collier, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Transplantation and Cellular Therapy|September 21, 2024
Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell TherapyAasha I Hoogland, Anna Barata, Xiaoyin Li, et al.
Pageof 42

Showing results (381-390 of 420) with videos related to

Sort By:
Pageof 42
Transplantation and Cellular Therapy|April 4, 2022
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell TherapyAasha I Hoogland, Anna Barata, Jennifer Logue, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 9, 2019
Respiratory health status is associated with treatment outcomes in pulmonary tuberculosisA N Gupte, S Selvaraju, M Paradkar, et al.
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Cancer Medicine|February 28, 2021
Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucelAasha I Hoogland, Reena V Jayani, Aaron Collier, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Transplantation and Cellular Therapy|September 21, 2024
Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell TherapyAasha I Hoogland, Anna Barata, Xiaoyin Li, et al.
Pageof 42